Tag:
AVI Biopharma
Latest Headlines
Latest Headlines
AVI tanks after positive PhIIb fails to improve outcomes for DMD
AVI Biopharma heralded the news that its lead therapy hit the primary endpoint in a Phase IIb study, increasing levels of dystrophin in a tiny trial for Duchenne muscular dystrophy, but the boys did not experience a significant improvement in walking ability,
Setbacks force AVI BioPharma to ax staffers in restructuring effort
RNA drug developer AVI BioPharma buried the lead in a press release Friday. After touting a new hire--Jayant Aphale, Ph.D.--at some length, the Bothell, WA-based biotech tersely noted that 28% of the
Investigators herald antisense breakthrough on muscular dystrophy
An early-stage study of an AVI Biopharma treatment using antisense oligonucleotides, or strips of genetic code, demonstrated that it successfully spurred the production of a missing muscle protein
Former Genentech CEO Levinson joins Amyris' board
> AVI BioPharma's board has appointed CFO J. David Boyle II as interim president and CEO. The appointment follows former CEO and director Leslie Hudson's resignation. The board plans to initiate a
AVI finds new prospects in Seattle cluster
Over the past year AVI Biopharma's fortunes have been transformed. Its stock price has more than tripled as it has pushed new RNA programs for Duchenne Muscular Dystrophy and the Ebola and Marburg
AVI Biopharma shares down on stock offering
When Oregon biotech AVI BioPharma announced earlier this week a public offering of shares of its common stock, it's share price closed at $1.78. The next day its share price dropped 25 percent on
Bullish AVI Biopharma plots HQ move to Seattle
With its stock price up and its RNA technology showing promise for Duchenne Muscular Dystrophy and bioterror programs, a bullish AVI Biopharma announced that it will move its headquarters staff and
